MEMORY PHARMACEUTICALS REPORTS RESULTS FROM STUDY OF MEM 1003 IN ALZHEIMER'S PATIENTS

Memory Pharmaceuticals has announced preliminary results from its Phase Ib safety and tolerability study of MEM 1003 in Alzheimer's disease patients. In the study, MEM 1003 was safe and generally well-tolerated at the dose ranges tested. In addition, the results demonstrated that MEM 1003 is cognitively safe in patients with Alzheimer's disease.

The study consisted of two segments — a double-blind dose-escalation segment and a double-blind multiple-dose treatment segment. In the first segment of the study, MEM 1003 or placebo was administered to 49 patients two times on one day. Patients in this segment of the study were treated at escalating doses of MEM 1003 that reached 120 mg per dose two times per day. In the double-blind multiple dose treatment segment, 32 patients received 120 mg of MEM 1003 or placebo twice daily for a period of ten days.